Untitled Document Stemagen Corporation

Healing begins with a Single Cell.™

Who We Are

Dr. Samuel Wood, CEO StemagenSamuel H. Wood, M.D., Ph.D.
CEO, Stemagen

Dr. Samuel Wood, one of the country’s most highly respected fertility specialists, founded Stemagen in an effort to help harness the power and promise of stem cell technology. While directing a internationally renowned fertility center located in La Jolla, California, Dr. Wood became acutely aware of the tragedy of unused frozen embryos being discarded when couples completed their infertility treatment and realized that these embryos could serve as the starting point for the development of treatment for presently incurable degenerative diseases like Parkinson’s and Alzheimer’s Disease.

Dr. Wood's distinguished academic background also includes a Master's degree in Psychology, a Ph.D. in Biochemistry and Molecular Biophysics, and an M.B.A. He is Board Certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility and has served on the Clinical Faculty at UCSD. Dr. Wood has been featured in many local newspaper, radio, and television stories as well as several nationally broadcast stories, including Frontline, Good Morning America, and the Discovery Channel as well as a BBC documentary that has now been seen in over 50 countries.

As an acclaimed reproductive endocrinologist, Dr. Wood is also Medical Director of The Reproductive Sciences Center in La Jolla, California. He is also founder and director of The Select Surrogate, a well-respected surrogacy program.

A complete biography and CV of Dr. Wood is available here.

Dr. Andrew French, CSO StemagenAndrew French, Ph.D.
CSO, Stemagen

With almost 20 years experience in both academia and private industry, Andrew French, Ph.D., Stemagen’s Chief Scientific Officer, is one of the world’s most accomplished experts in mammalian cloning. Over the last six years, Dr. French has held senior research positions in the Centre for Early Human Development at Monash Institute of Reproduction and Development, Monash University where he was Project Leader for Reproductive Technologies and managed the R&D activities of 10 staff and over 20 students.

Dr. French’s personal research interests and accomplishments in the field of reproductive biotechnology have included the production and characterization of laboratory and domestic transgenic animals, genetic engineering for improved growth rates and xenotransplantation. His group was the first to generate elite transgenic and non-transgenic dairy cows using nuclear transfer in Australia. He has published over 40 publications in scientific journals and books and holds several patents. In 2005, Andrew joined Stemagen to manage the development of proprietary methods for the isolation of human embryonic stem cell lines and their use for cell-based therapeutics.

More About Us

To find out more about us and the research we are conducting here at Stemagen, please come back to our web site often or, better still, sign up for our electronic newsletter. It contains information not only about Stemagen but also about important research findings from other stem cell laboratories throughout the world. To receive our newsletter, just send us an email at subscribe@stemagen.com.

To ask a specific question, e-mail us at info@stemagen.com. Although we are not necessarily able to answer every question we get, we try to answer some of them in a column in our newsletter.

Thank you for your interest.